Listen
ENBREL (etanercept), anti-TNF α
RHEUMATOLOGY - Investigation
Opinions on drugs -
Posted on
Dec 12 2016
Reason for request
Re-assessment of the actual benefit
Insufficient actual benefit in the treatment of active, severe and progressive rheumatoid arthritis in adults not previously treated with methotrexate or another conventional disease-modifying drug.
- ENBREL, HUMIRA, REMICADE have Marketing Authorisation in first-line treatment of active, severe and progressive rheumatoid arthritis, in patients not previously treated with methotrexate (MTX) or for REMICADE, with another conventional disease-modifying drug.
- It is preferable, at an early stage, to expect a response to first-line treatment with methotrexate, with a treatment adjustment strategy, and to introduce, where applicable, a targeted treatment in case of insufficient response or intolerance of methotrexate.
- ENBREL, HUMIRA, REMICADE have no role in the treatment strategy for patients who have not been previously treated with MTX or with other conventional treatments.
Clinical Benefit
| Insufficient |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
